Posted by Michael Wonder on 26 Feb 2025
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection (final guidance)
26 February 2025 - NICE has published final evidence-based recommendations on the use of osimertinib mesylate (Tagrisso) for the adjuvant treatment of adults with stage 1b to 3a non‑small‑cell lung cancer after complete tumour resection.
Osimertinib mesylate is recommended as an option for the adjuvant treatment of adults with stage 1b to 3a non‑small‑cell lung cancer (NSCLC) after complete tumour resection. It is for those whose tumours have an EGFR exon 19 deletion mutation or qn EGFR exon 21 (L858R) substitution mutation.
Osimertinib mesylate is only recommended if treatment is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity and AstraZeneca provides it according to the commercial arrangement.
